Skip to content
OpenCapital
Get started

BioLife Solutions BLFS Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price at other companies

STERIS logo
STERISSTE
——

Other financials

Income statement

See full
Revenue$27.5M+24.7%
Gross profit$17.5M+18.2%
Operating income$27.0K+105%
Net income$1.2M+365%
EPS (diluted)$0.02—

Balance sheet

See full
Cash & equivalents$22.8M-65.9%
Total debt$17.4M-35.6%
Total equity$372.2M+5.6%
Total assets$400.9M+1.5%

Cash flow

See full
Operating cash flow-$491.0K-128%
CapEx$167.0K-4.6%
Free cash flow-$658.0K-142%

Valuation

See full
Market cap$1.34B+33.1%
Enterprise value$1.34B+38.1%
P/S13.5×+0.6×

Profitability

See full
Gross margin66.9%—
Operating margin-16.7%—
Net margin-68.7%—
FCF margin-15.9%+18.7pp

Returns & leverage

See full
Return on equity-14.5%-4.7pp
Debt / equity0×0.0×
Current ratio7.3×+2.6×

Where this comes from

Reported directly by BioLife Solutions in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.

The official record: BioLife Solutions’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioLife Solutions's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioLife Solutions's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price?
BioLife Solutions (BLFS) reported share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price of $4.08 in Q1 2026.
How has BioLife Solutions's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price changed year-over-year?
BioLife Solutions's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price increased by 86.3% year-over-year, from $2.19 to $4.08.
What is the long-term trend for BioLife Solutions's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price?
Over 2 years (2023 to 2025), BioLife Solutions's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price has grown at a 0.2% compound annual growth rate (CAGR), from $2.21 to $2.22.